According to the Zhitong Finance APP, Jacobson Pharma (02633) announced that the Group expects, for the six months ended September 30, 2024, a profit from continuing operations increasing by over 40% compared to the same period last year.

The significant increase in interim profits from continuing operations is mainly attributed to the solid performance of the non-patented pharmaceutical business in the public and private sectors, as well as the revenue contribution from new authorized products and strong new product launches. The improvement in production facility operating leverage and cost-saving measures also contribute to the related growth.

Due to the physical distribution of JBM Healthcare (02161) shares as a special dividend, the company will no longer consolidate the performance of JBM Healthcare and its subsidiaries in the financial statements. It is expected that the company's equity holders' share of profit for the mid-period will slightly decrease by no more than 9% compared to the same period last year.